Typhim VI 25 MCG/0.5 ML vial 10ML
Ended Awarded
- Contract number
- SPE2DB25FQ1WN
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,316
Award facts
- Contract value 100% obligated
- $4,316.45 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML Vial (10ML), a typhoid vaccine product. This firm fixed-price delivery order, valued at $4,316.45, represents a non-competitive set-aside award and is scheduled for completion by July 22, 2025. The product will be performed and delivered from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor that primarily serves the Defense Logistics Agency and its Medical Supply Chain. The company's federal contract portfolio demonstrates substantial expertise in fulfilling military healthcare supply requirements, including vaccines, brand-name and generic medications, and specialized medical commodities across multiple therapeutic domains. The DLA's reliance on AmerisourceBergen through both its prime IDC and individual delivery orders reflects the contractor's established capability to meet federal pharmaceutical procurement requirements and support defense health operations worldwide.
Quick answers
Who was awarded contract SPE2DB25FQ1WN?
SPE2DB25FQ1WN was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on July 21, 2025.
How much is contract SPE2DB25FQ1WN worth?
The government has obligated $4,316 on SPE2DB25FQ1WN.
Is contract SPE2DB25FQ1WN an order under another contract?
Yes. SPE2DB25FQ1WN is a delivery order under SPE2DB22D3011, an indefinite delivery contract.
Was contract SPE2DB25FQ1WN competed?
The extent of competition for SPE2DB25FQ1WN was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award